In recent years, immune card control point drugs have provided a new therapy for CRC, especially the programmed death 1 (PD-1)/programmed death ligand-1(PD-L1) monoclonal antibody as an immunodetection point inhibitor and an antibody-type tumor immune drug [13, 14]. Here, CD274 is linked to neoplasm.